BERWYN, PA — Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) announced it recently signed a clinical trial agreement with Altasciences Company, Inc. for a First in Human study investigating Epoladerm™ for pain associated with osteoarthritis of the knee.
The study will take place in Canada with a CTA filing and enrollment of the first patient anticipated by Q2 of 2022.
“Performing trials in Canada is an efficient and cost-effective way for Virpax to add robust data in support of the 505(b)(2) FDA approval pathway for Epoladerm™ . Through partners like Altasciences, we may strategically accelerate our optimized drug delivery therapeutic candidates through pre-clinical and clinical development,” commented Chairman & CEO Anthony P. Mack.
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.